Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: October Update

Performance overview

Value at beginning of month: $160,225.58

Value at end of month: $131,204.33

Month over month change: -18.11%

Total IRR: 16.40%

Related indices, monthly change

NASDAQ: -10.93%

IVV (iShares Core S&P 500): -8.76%

IBB (iShares NASDAQ Biotechnology Index): -15.03%

MXI (iShares Global Materials): -11.53%

VEGI (iShares MSCI Global Agriculture Producers): -8.77%

ICLN (iShares Clean Energy): -6.05%

Individual performances


Ouch. This month really hurt the index, as it fell from almost yearly highs to a negative year-to-date return. Though the index had a rough month, it was a market as a whole that cratered, with biotech stocks suffering a bit more than others. Almost every single position lost value (way to go Dyadic!), with some losing almost a third of their value. Hopefully November is better!

Changes made to index


You can view the index here.

Allocation as of October 26, 2018


Calvin Schmidt Synthetic Biology Index: November Update

Synthetic biology investors are a mix of life sciences and traditional technology investors